Dr. Reddy's Laboratories Limited filings document its U.S. reporting as a foreign private issuer with American depositary receipts listed on the New York Stock Exchange. Recent Form 6-K reports furnish exchange intimations and exhibits submitted to Indian exchanges and the NYSE, including board-meeting notices and other current-report disclosures.
The filing record centers on Rule 13a-16 and 15d-16 submissions, Form 20-F reporting status, governance communications, and public-company notices tied to Dr. Reddy's pharmaceutical operations and securities across India and the United States.
DR REDDYS LABORATORIES LTD (RDY) reports the allotment of 375 equity shares of face value Re.1 each on September 10, 2026, to employees exercising stock options under the Dr. Reddy’s Employees ADR Stock Option Scheme, 2007. These fully paid shares rank pari passu with existing equity shares.
Total issued shares after this allotment are 834,681,285, with total issued share capital of Rs. 834,681,285. The paid-up capital reflects 834,680,285 equity shares, with a difference of 1,000 shares due to forfeited shares from September 1988.
DR. REDDY’S LABORATORIES LIMITED (symbol RDY) reports the allotment of 4,110 equity shares of face value Re.1 each on August 26, 2026 to eligible employees following exercise of stock options under the Dr. Reddy’s Employees Stock Option Scheme, 2002. These fully paid shares are equity shares that rank pari passu with existing shares. After this issuance, total issued shares are 83,46,80,910 and total issued share capital is Rs. 83,46,80,910, while total paid-up capital is 83,46,79,910 equity shares of Re.1 each, aggregating to Rs. 83,46,79,910, reflecting 1,000 forfeited shares from September 1988.
Dr. Reddy’s Laboratories Limited reported the outcome of a United States Food & Drug Administration inspection at its active pharmaceutical ingredient manufacturing facility in Mirfield, West Yorkshire, United Kingdom. The inspection has been classified as “Voluntary Action Indicated (VAI)”, and the USFDA has concluded and officially closed the inspection under 21 CFR 20.64(d)(3). This indicates the facility remains under normal regulatory status with only voluntary corrective actions, if any, expected from the company.
Dr. Reddy’s Laboratories Limited reported that the United States Food & Drug Administration completed a GMP inspection of its formulations manufacturing facility FTO-3 in Bachupally, Hyderabad. The inspection took place from August 6, 2026 to August 14, 2026. Following the inspection, the company received a Form 483 with four observations, which it states will be addressed within the stipulated timeline.
Dr. Reddy’s Laboratories Limited reports that Mr. Deepak Sapra has resigned from his role as CEO, API and Services, and as a member of the company’s Senior Management Personnel to pursue opportunities outside the company. He will remain in employment and part of senior management until the close of business hours on November 12, 2026, providing transition support and handover of responsibilities.
The company states that the disclosure is made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Mr. Sapra’s resignation letter notes his association with Dr. Reddy’s for more than 23 years since 2003 and expresses gratitude for the learning, guidance and support during his tenure.
Dr. Reddy’s Laboratories Limited reported that it has terminated its agreement dated February 11, 2022 with Novartis India Limited covering the distribution and promotion of select brands in India. The termination is linked to a change in the controlling shareholding of Novartis India Limited.
Dr. Reddy’s stated that it will continue to commercialize the brands covered by this agreement in India until September 30, 2026, after which the existing arrangement will cease. No financial impact, volumes, or brand list are specified in the disclosure.
Dr. Reddy’s Laboratories received U.S. FDA approval for its rituximab biosimilar, a biosimilar to Rituxan (rituximab), for the U.S. market. The product was developed, manufactured and submitted by Dr. Reddy’s, and the approval followed a successful Pre-License Inspection at its biologics facility in Bachupally, Hyderabad.
Under an exclusive commercialization agreement, Fresenius Kabi will market the product in the United States, a key global pharmaceutical market. The rituximab biosimilar is already commercialized in India, the European Union, the United Kingdom and more than 25 emerging markets, with additional approvals in Switzerland and Canada, reinforcing Dr. Reddy’s strategy to expand its biosimilars portfolio in oncology and autoimmune diseases.
Dr. Reddy’s Laboratories Limited reports that the United States Food & Drug Administration (USFDA) has completed a Pre-Approval Inspection (PAI) and Good Manufacturing Practices (GMP) inspection at its FTO-SEZ Process Unit-02 facility in Srikakulam, Andhra Pradesh. The regulatory review was carried out between July 20, 2026 and July 29, 2026.
Following the inspection, the company received an FDA Form 483 containing three observations. Dr. Reddy’s states that these observations will be addressed within the stipulated timeline, and the update has been shared with the Indian stock exchanges and the New York Stock Exchange for information and records.
Dr. Reddy’s Laboratories reported Q1 FY27 consolidated revenues of ₹8,071 crores (US$853 million), down 5.6% year-on-year but up 7.4% sequentially. EBITDA margin was 12.5%, compressed by lower lenalidomide sales and a ₹240 crores provision for semaglutide API-related inventory and other costs. Excluding this provision, EBITDA margin was 15.4% and gross margin 49.4% versus a reported 46.5%. Profit after tax attributable to equity holders was ₹443 crores (US$47 million), a 5.5% margin, and diluted EPS was ₹5.32.
Base business excluding lenalidomide delivered healthy double-digit growth across key geographies. North America Generics generated US$236 million, 27% of revenue, down 41% year-on-year but up 19% sequentially. India revenues were ₹1,718 crores, up 17% year-on-year, and Emerging Markets reached ₹1,833 crores, up 31%. Europe, including NRT, recorded €131 million, broadly flat year-on-year, while PSAI API revenues were US$91 million, down 5%.
Management is addressing semaglutide API out-of-specification issues, targeting commercial supply resumption by November and expecting 6–7 million pens to be available between November and March, with no patient safety concerns reported. The biologics facility in Bachupally recently underwent a USFDA Pre-License Inspection, resulting in seven Form 483 observations that have been answered; the abatacept BLA retains a December 2026 goal date. The company ended the quarter with operating working capital of ₹14,353 crores, net cash of ₹3,057 crores and capex of ₹307 crores, and reiterated medium-term aims for base-business EBITDA margins around 20%, R&D at 7–8% of sales and a 24–25% effective tax rate.
Dr. Reddy’s Laboratories Limited reports that shareholders at the 42nd Annual General Meeting approved several governance resolutions. Dr. K P Krishnan was re-appointed as an Independent Director for a second five-year term from January 7, 2027 to January 6, 2032, not liable to retire by rotation.
Shareholders also approved the appointment of Mr. Srikanth Velamakanni as an Independent Director for five years from July 1, 2026 to June 30, 2031, also not liable to retire by rotation. Both directors are stated to be unrelated to existing directors and not debarred under SEBI or other authorities, and they meet applicable independence criteria.
In addition, M/s Deloitte Haskins & Sells LLP was appointed as Statutory Auditors for five consecutive years, from the conclusion of the 42nd AGM until the conclusion of the 47th AGM.